Adherium Limited (ASX:ADR) Raises $2.6M through Convertible Notes
Capital Raising Details
Adherium Limited (ASX:ADR) has secured $2.6 million through the issuance of approximately 2,600,000 convertible notes. Cornerstone investors Bioscience Managers and Trudell Medical International each contributed $1.2 million to the capital raise. The funds will support the ongoing roll-out of Adherium’s proprietary Hailie® Smartinhaler® platform in the United States.
Executive Comments
Interim CEO and Independent Non-Executive Director Jeremy Curnock Cook stated, “We are excited by the ongoing commitment of Bioscience Managers and Trudell Medical International, who have supported us on the journey towards commercialisation of the Hailie® Smartinhaler® platform in the United States.”
Reaffirmed Guidance
The board has reaffirmed its guidance, expecting to onboard an additional 1,800 active patients over the next six months and reach 9,000 active patients by the end of 2025.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.